Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process

Journal of Sexual Medicine

Volumn 7, Issue 3, 2010, Pages 1247-1253

  Vicari, Enzo ^a   La Vignera, Sandro ^a   Condorelli, Rosita ^a   Calogero, Aldo Eugenio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antioxidant; Endothelium; Erectile Dysfunction; IIEF; Sildenafil

Indexed keywords

ANTIOXIDANT; ARGININE; EZEREX; NICOTINIC ACID; NITRIC OXIDE; OXYGEN RADICAL; PHOSPHODIESTERASE V INHIBITOR; PROPIONYLCARNITINE; SILDENAFIL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOAVAILABILITY; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER FLOWMETRY; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LEG ARTERY; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 77950843974     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01420.x     Document Type: Article

References (30)

1. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985, 26:181-4.
2. Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract 1999, 53:363-8.
3. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004, 43:179-84.
4. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003, 44:360-4.
5. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002, 4:397-401.
6. Vicari E, Arcidiacono G, Di Pino L, Signorelli S, Arancio A, Sorrentino F, Battiato C, D'Agata R, Calogero AE. Incidence of extragenital vascular disease in patients with erectile dysfunction of arterial origin. Int J Impot Res 2005, 17:277-82.
7. Vicari E, Di Pino L, La Vignera S, Fratantonio E, Signorelli S, Battiato C, Calogero AE. Peak systolic velocity in patients with arterial erectile dysfunction and peripheral arterial disease. Int J Impot Res 2006, 18:175-9.
8. Basar M, Atan A, Tekdogan UY, Batislam E. A classification based on peak systolic velocity and end diastolic velocity predict sildenafil citrate success. Scand J Urol Nephrol 2003, 37:502-6.
9. Mulhall J, Barnas J, Aviv N, Anderson M, Parker M. Sildenafil citrate response correlates with the nature and the severity of penile vascular insufficiency. J Sex Med 2005, 2:104-8.
10. Carsson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: An update. Urology 2002, 60:12-27.
11. Carson CC. PDE5 inhibitors: Are there differences? Can J Urol 2006, 13(1):34-9. suppl
12. Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, Wong DG. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med 2006, 3:492-503.
13. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002, 60(2):28-38. suppl
14. Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005, 95:366-70.
15. de Tejada IS. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 2004, 16(1):S40-2. suppl
16. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: An update. Eur Urol 2006, 49:806-15.
17. Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004, 20:1377-84.
18. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, Lenzi A. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: A double-blind, placebo-controlled study. Eur Urol 2007, 52:1768-74.
19. Vicari E, Malaguarnera M, La Vignera S, Calzavara F, Battiato C, Calogero AE. Efficacy and limits of sildenafil citrate in patients with arterial erectile dysfunction: Role of peripheral arterial disease and cardiovascular comorbidities. Asian J Androl 2008, 10:847-53.
20. Chung WS, Shim BS, Park YY. Hemodynamic insult by vascular risk factors and pharmacological erection in men with erectile dysfunction: Doppler sonography study. World J Urol 2000, 18:427-30.
21. Gareth WL, Phillips MRCP. Review of arterial vascular ultrasound. World J Surg 2000, 24:232-40.
22. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: A study on 100 non-responders. Eur Urol 2005, 47:518-22.
23. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 2006, 3:28-36.
24. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloch IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Dysfunction. Urology 1999, 54:346-51.
25. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: Pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008, 48:79-106.
26. Burnett A, Musicki B, Jin L, Bivalacqua T. Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 2006, 10:445-57.
27. Musicki B, Burrett AL. eNOS function and dysfunction in the penis. Exp Biol Med 2006, 231:154-65.
28. Musicki B, Ross AE, Champion HC, Burnett AL, Bivalacqua TJ. Post-translational modification of constitutive nitric oxide synthase in the penis. J Androl 2009, Epub ahead of print
29. Böger RH, Ron ES. L-arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005, 10:14-23.
30. Komori K, Tsujimura A, Takao T, Matsuoka Y, Miyagawa Y, Takada S, Nonomura N, Okuyama A. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3′,5′-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. J Sex Med 2008, 5:1623-35.